Open AccessComparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
Author(s) -
Rozalina G. McCoy,
Holly K. Van Houten,
Yihong Deng,
Pinar Karaca Mandic,
Joseph S. Ross,
Víctor M. Montori,
Nilay D. Shah
Publication year - 2021
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.35792
Subject(s) - medicine , medicare advantage , type 2 diabetes , logistic regression , diabetes mellitus , medical prescription , retrospective cohort study , pharmacoepidemiology , medicare part d , emergency medicine , prescription drug , health care , pharmacology , endocrinology , economics , economic growth
Key Points Question Were there differences in the initiation of treatment with newer medications to lower glucose levels between patients with type 2 diabetes insured by Medicare Advantage and those insured by commercial health plans from 2016 to 2019? Findings In this cohort study of 382 574 adults with type 2 diabetes aged 58 to 66 years, rates of initiation of glucagonlike peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors were lower among Medicare Advantage enrollees than among commercial health insurance plan enrollees. Meaning These findings suggest that a better understanding of nonclinical factors contributing to treatment selection and efforts to promote equity in diabetes management are needed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom